← All trials
NCT03069131
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2017
- Primary completion
- Nov 1, 2020
- Completion date
- May 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Franche-ComtéLead sponsor
- University of RennesOverall official - principal investigator
- University of AntwerpOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- University of BurgundyOverall official - principal investigator
- University of ReimsOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- EurofinsCollaborator
- Alfa WassermannCollaborator
- University of LilleOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.